Day: June 20, 2025

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. “Inclusion in the Russell 3000® Index is an important milestone in Emergent’s ongoing transformation,” said Joe Papa, president and chief executive officer of Emergent BioSolutions. “This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our commitment to strong execution, financial stability, and long-term value creation for our shareholders.” The annual Russell U.S. Indexes reconstitution...

“Scope Ratings” GmbH (hereinafter – Scope) has downgraded the issuer rating of closed-end investment company intended for informed investors UAB “Atsinaujinančios energetikos investicijos” from B+ to B-. Scope has also downgraded the senior unsecured debt rating from BB- to B. All ratings have been placed under review with the outcome dependent on the progress of the issuer’s debt refinancing process. For more information, please see: https://scoperatings.com/ratings-and-research/rating/EN/178932 Contact person for further information: Mantas Auruškevičius Manager of the Investment Company mantas.auruskevicius@lordslb.lt

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has entered into a new loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5million, administered through multiple advances for the purpose of continued clinical development of TUS. The Loan Agreement constitutes a “related-party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) as Hanmi is...

Series  RIKB 28 1115 RIKB 38 0215Settlement Date  06/25/2025 06/25/2025Total Amount Allocated (MM)  4,880 1,120All Bids Awarded At (Price / Yield)  93.000 / 7.390 96.280 / 6.950Total Number of Bids Received  20 34Total Amount of All Bids Received (MM)  5,830 5,151Total Number of Successful Bids  16 9Number of Bids Allocated in Full  16 9Lowest Price / Highest Yield Allocated  93.000 / 7.390 96.280 / 6.950Highest Price / Lowest Yield Allocated  93.110 / 7.350 96.650 / 6.900Lowest Price / Highest Yield Allocated in Full  93.000 / 7.390 96.280 / 6.950Weighted Average of Successful Bids (Price/Yield)  93.047 / 7.380 96.324 / 6.940Best Bid (Price / Yield)  93.110 / 7.350 96.650 / 6.900Worst Bid (Price / Yield)  92.927 / 7.420 95.650 / 7.020Weighted Average of All Bids Received (Price / Yield)  93.032 / 7.380 95.986 / 6.980Percentage...

VANCOUVER, BC, June 20, 2025 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“Digital Asset Technologies” or the “Company”) and its portfolio company LiquidLink AI Corp. (“LinkLink”), strongly supports the U.S. Senate’s passage of the GENIUS Act (S.1582) — a landmark bill establishing the first comprehensive federal regulatory framework for payment stablecoins. The legislation marks a definitive turning point for the digital asset industry and lays the foundation for global programmable money, institutional grade stablecoins, and real-world asset (RWA) tokenization. The GENIUS Act not only positions the United States alongside every other G20 nation that has developed or is piloting programmable money systems — including Europe’s MiCA framework and CBDC programs in China, Japan, and Canada...

TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is delighted to announce that on June 20, 2025, the Company has agreed in principle to the terms and conditions (the “Term Sheet”) for a copper concentrates prepayment facility of up to US$200m (the “Facility”) offered by Trafigura Pte Ltd. (the “Lender”), subject to conditions summarised below. This Facility is aimed to secure the financial requirements needed by the Company to complete all necessary permitting and further investment over the next 18 months to advance the Rovina Valley copper-gold project (the “Project”). The Lender intends to assist in syndication of a consortium to provide the Company with additional debt component of up to US$200m upon reaching the construction phase of the Company’s Rovina Valley Project. Mr....

– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – – Underscores the value of recent Evoke acquisition that builds upon Firefly’s FDA-cleared BNA™ AI platform and unique integrated normative reference group – – It’s well accepted that earlier dementia course detection can improve outcomes and open up additional treatment opportunities – KENMORE, N.Y., June 20, 2025 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders,...

GUANGZHOU, China, June 20, 2025 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading Urban Air Mobility (UAM) technology platform company, announced today that the Company has entered into a strategic cooperation agreement with the Management Committee of Jingyue High-tech Industrial Development Zone (“Jingyue Hi-tech Zone”) in Changchun, Jilin Province. The two parties will jointly develop a provincial-level demonstration zone for low-altitude economic development, integrating industrial development, technological innovation, and real-world application scenarios. The platform company, Jilin Aerospace Industry Development Investment Co., Ltd., agrees to place an order for 41 units of EHang’s EH216-S pilotless eVTOLs, according to the Cooperation Agreement. These units will be deployed...

Tel Aviv, Israel, June 20, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that the TSX Venture Exchange (“TSXV”) has approved the previously announced acquisition (the “Proposed Transaction”) by Impact Acquisitions Corp. (TSXV: IMPC.P) (“Impact”), of 100% of the equity interests of Fort Products Limited (“Fort”), a wholly-owned U.K.-based subsidiary of Jeffs’ Brands, in exchange for an initial 75.02%, and up to an 83.29% contingent upon meeting predetermined milestones. Upon completion of the Proposed Transaction, Impact will issue 100,000,000 common shares to the Company at a deemed price per share of CAD $0.171246 for deemed aggregate consideration of approximately CAD$17.1 million (approximately...

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trial European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U.  CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom (Rezdiffra) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission decision is...